vs
Ingevity Corp（NGVT）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Ingevity Corp的季度营收约是Pacira BioSciences, Inc.的1.0倍（$185.4M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -45.6%，领先47.3%），Ingevity Corp同比增速更快（36.7% vs 5.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -26.2%）
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
NGVT vs PCRX — 直观对比
营收规模更大
NGVT
是对方的1.0倍
$177.4M
营收增速更快
NGVT
高出31.7%
5.0%
净利率更高
PCRX
高出47.3%
-45.6%
两年增速更快
PCRX
近两年复合增速
-26.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $185.4M | $177.4M |
| 净利润 | $-84.6M | $2.9M |
| 毛利率 | 41.2% | — |
| 营业利润率 | -47.7% | 3.9% |
| 净利率 | -45.6% | 1.6% |
| 营收同比 | 36.7% | 5.0% |
| 净利润同比 | -609.6% | — |
| 每股收益（稀释后） | $-2.33 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NGVTPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $185.4M | $196.9M | ||
| Q3 25 | $333.1M | $179.5M | ||
| Q2 25 | $365.1M | $181.1M | ||
| Q1 25 | $284.0M | $168.9M | ||
| Q4 24 | $135.6M | $187.3M | ||
| Q3 24 | $333.8M | $168.6M | ||
| Q2 24 | $390.6M | $178.0M |
净利润NGVTPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-84.6M | — | ||
| Q3 25 | $43.5M | $5.4M | ||
| Q2 25 | $-146.5M | $-4.8M | ||
| Q1 25 | $20.5M | $4.8M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $-107.2M | $-143.5M | ||
| Q2 24 | $-283.7M | $18.9M |
毛利率NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | 41.2% | 79.5% | ||
| Q3 25 | 40.2% | 80.9% | ||
| Q2 25 | 37.8% | 77.4% | ||
| Q1 25 | 39.9% | 79.7% | ||
| Q4 24 | 81.3% | 78.7% | ||
| Q3 24 | 39.4% | 76.9% | ||
| Q2 24 | 31.5% | 75.1% |
营业利润率NGVTPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | -47.7% | 1.2% | ||
| Q3 25 | 18.7% | 3.5% | ||
| Q2 25 | -39.1% | 4.7% | ||
| Q1 25 | 9.4% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 33.0% | -82.8% | ||
| Q2 24 | 25.9% | 15.9% |
净利率NGVTPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | -45.6% | — | ||
| Q3 25 | 13.1% | 3.0% | ||
| Q2 25 | -40.1% | -2.7% | ||
| Q1 25 | 7.2% | 2.8% | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | -32.1% | -85.1% | ||
| Q2 24 | -72.6% | 10.6% |
每股收益（稀释后）NGVTPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-2.33 | $0.05 | ||
| Q3 25 | $1.18 | $0.12 | ||
| Q2 25 | $-4.02 | $-0.11 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.44 | $0.38 | ||
| Q3 24 | $-2.94 | $-3.11 | ||
| Q2 24 | $-7.81 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $144.3M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $29.7M | $653.9M |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 39.10× | — |
8季度趋势，按日历期对齐
现金及短期投资NGVTPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $78.1M | $238.4M | ||
| Q3 25 | $83.4M | $246.3M | ||
| Q2 25 | $76.9M | $445.9M | ||
| Q1 25 | $71.5M | $493.6M | ||
| Q4 24 | $68.0M | $484.6M | ||
| Q3 24 | $135.5M | $453.8M | ||
| Q2 24 | $107.4M | $404.2M |
总债务NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $372.2M | ||
| Q3 25 | $1.2B | $376.7M | ||
| Q2 25 | $1.2B | $580.5M | ||
| Q1 25 | $1.3B | $583.4M | ||
| Q4 24 | $1.3B | $585.3M | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
股东权益NGVTPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $29.7M | $693.1M | ||
| Q3 25 | $138.1M | $727.2M | ||
| Q2 25 | $120.7M | $757.8M | ||
| Q1 25 | $234.6M | $798.5M | ||
| Q4 24 | $195.2M | $778.3M | ||
| Q3 24 | $214.5M | $749.6M | ||
| Q2 24 | $284.8M | $879.3M |
总资产NGVTPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.0B | $1.6B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
负债/权益比NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | 39.10× | 0.54× | ||
| Q3 25 | 8.39× | 0.52× | ||
| Q2 25 | 10.24× | 0.77× | ||
| Q1 25 | 5.68× | 0.73× | ||
| Q4 24 | 6.86× | 0.75× | ||
| Q3 24 | 6.52× | — | ||
| Q2 24 | 4.92× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.1M | — |
| 自由现金流经营现金流 - 资本支出 | $73.5M | — |
| 自由现金流率自由现金流/营收 | 39.6% | — |
| 资本支出强度资本支出/营收 | 12.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $273.5M | — |
8季度趋势，按日历期对齐
经营现金流NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | $97.1M | $43.7M | ||
| Q3 25 | $129.7M | $60.8M | ||
| Q2 25 | $79.0M | $12.0M | ||
| Q1 25 | $25.4M | $35.5M | ||
| Q4 24 | $64.5M | $33.1M | ||
| Q3 24 | $46.5M | $53.9M | ||
| Q2 24 | $29.7M | $53.2M |
自由现金流NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | $73.5M | $43.5M | ||
| Q3 25 | $117.8M | $57.0M | ||
| Q2 25 | $66.8M | $9.3M | ||
| Q1 25 | $15.4M | $26.9M | ||
| Q4 24 | $39.6M | $31.0M | ||
| Q3 24 | $28.5M | $49.8M | ||
| Q2 24 | $11.6M | $51.6M |
自由现金流率NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | 39.6% | 22.1% | ||
| Q3 25 | 35.4% | 31.7% | ||
| Q2 25 | 18.3% | 5.1% | ||
| Q1 25 | 5.4% | 15.9% | ||
| Q4 24 | 29.2% | 16.6% | ||
| Q3 24 | 8.5% | 29.6% | ||
| Q2 24 | 3.0% | 29.0% |
资本支出强度NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | 12.7% | 0.1% | ||
| Q3 25 | 3.6% | 2.2% | ||
| Q2 25 | 3.3% | 1.5% | ||
| Q1 25 | 3.5% | 5.1% | ||
| Q4 24 | 18.4% | 1.1% | ||
| Q3 24 | 5.4% | 2.4% | ||
| Q2 24 | 4.6% | 0.9% |
现金转化率NGVTPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.98× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | 7.37× | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
